)
Visual
test
Traws Pharma
Traws Pharma (TRAW) investor relations material
Traws Pharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Cash and cash equivalents were $6.4 million as of September 30, 2025, with an accumulated deficit of $632.5 million.
Substantial doubt exists about the ability to continue as a going concern for more than one year without additional funding.
Advanced Phase 2 studies for ratutrelvir, a ritonavir-free protease inhibitor for acute and Long COVID, with topline data expected by year-end 2025.
The company is a clinical-stage biopharmaceutical firm with four clinical programs, focusing on respiratory viral diseases and cancer.
Recent developments include the acquisition of assets from Viriom and the termination of a license agreement with Symbio.
Financial highlights
Net income for the nine months ended September 30, 2025, was $16.6 million, compared to a net loss of $136.6 million for the same period in 2024.
Revenue for the nine months ended September 30, 2025, was $2.8 million, up from $0.2 million in 2024, mainly due to the recognition of deferred revenue from the terminated Symbio agreement.
Operating expenses for the nine months ended September 30, 2025, were $13.3 million, down from $137.3 million in 2024, reflecting a significant decrease in acquired in-process R&D expenses.
R&D expenses decreased to $2.3 million for Q3 2025 from $5.1 million year-over-year, and G&A expenses fell to $1.7 million from $3.5 million.
Net loss for Q3 2025 was $4.0 million ($0.34 per share), improved from $8.5 million ($1.49 per share) in Q3 2024.
Outlook and guidance
The company expects to incur significant expenses and operating losses for the foreseeable future as it continues clinical development and seeks regulatory approvals.
Topline Phase 2 data for ratutrelvir expected by year-end 2025.
Management is exploring various funding sources, including equity, debt, and strategic partnerships, but there is no assurance of success.
Research and development expenditures are expected to increase as the TRX01 study progresses.
Actively seeking partnerships for legacy oncology assets to support further development.
How will Traws fund operations past Q4 2025?
How does ratutrelvir differentiate from PAXLOVID?
Update on rigosertib partnership discussions
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
Next Traws Pharma earnings date
Q4 202531 Mar, 2026
Traws Pharma
Next Traws Pharma earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Traws Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for respiratory viral diseases and cancer. The company focuses on creating novel treatments for conditions such as influenza, COVID-19, and various cancers, utilizing advanced drug development technologies including artificial intelligence and machine learning. The company is headquartered in Newtown, Pennsylvania, and its shares are listed on NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage